Article Text

Download PDFPDF
HLA-DR17 and Mooren’s ulcer in South India
  1. J R Zelefsky1,
  2. C J Taylor2,
  3. M Srinivasan3,
  4. S Peacock2,
  5. R S Goodman2,
  6. T Key2,
  7. P G Watson2,
  8. E T Cunningham4,5
  1. 1
    New York University School of Medicine, New York, New York, USA
  2. 2
    Tissue Typing Laboratory (Box 209), Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ UK
  3. 3
    Aravind Eye Hospital and PG Institute of Ophthalmology, Madurai, Tamil Nadu, India
  4. 4
    The Francis I Proctor Foundation, UCSF School of Medicine, San Francisco, California, USA
  5. 5
    The Uveitis Service, California Pacific Medical Center, San Francisco, CA, and Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA
  1. Dr C J Taylor, Tissue Typing Laboratory (Box 209), Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK; craig.taylor{at}addenbrookes.nhs.uk

Abstract

Objective: To investigate the association between Mooren’s ulcer and human leucocyte antigen (HLA) type DR17(3) in patients from the Tamil Nadu State of South India.

Methods: Blood samples from 38 patients with Mooren’s ulcer and 45 age- and sex-matched controls were obtained prospectively. HLA-DR and HLA-DQ typing was performed by PCR using sequence-specific primers.

Results: Fifteen (40%) of the patients with Mooren’s ulcer tested positive for HLA-DR17(3) compared with seven (16%) of the controls (p = 0.01). Seventeen (45%) of the patients also tested positive for the closely linked HLA-DQ2 compared with 11 (24%) of controls (p = 0.05). When adjusted for multiplicity, the correlation between HLA-DR17(3) and Mooren’s ulcer remained significant (p = 0.03).

Conclusions: These data demonstrate an association between HLA-DR17(3) and Mooren’s ulcer in South Indian patients, supporting autoimmune theories about the pathogenesis of the disorder.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: None declared.